PBM Patch for Postoperative Pain Relief After Urological Surgery
A Double-blind Randomized Controlled Clinical Study of the PBM Patch for Postoperative Pain Relief After Urological Surgery
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Shih-Chieh Chueh, Attending Physicia / Professor
- Telefonnummer: 62135 +886-2-3123456
- E-Mail: scchueh@ntu.edu.tw
Studienorte
-
-
Taipei City
-
Taipei, Taipei City, Taiwan, 100
- National Taiwan University Hospital
-
Kontakt:
- Shih-Chieh Chueh, M.D.
- Telefonnummer: 62135 +886-2-3123456
- E-Mail: scchueh@ntu.edu.tw
-
Taipei, Taipei City, Taiwan, 106
- National Taiwan University Cancer Center
-
Kontakt:
- Wei-Che Wu, M.D.
- Telefonnummer: +886972652979
- E-Mail: A01827@ntucc.gov.tw
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Patients aged 18 years or older undergoing unilateral nephroureterectomy with bladder cuff excision, or adrenalectomy (tumor size < 3.5 cm).
- Patients who are capable of clear verbal communication.
- Patients who are able to provide written informed consent.
Exclusion Criteria:
- Individuals with photosensitive constitution or those currently using photosensitizing medications.
- Individuals with a known history of severe allergy or contact dermatitis to medical adhesive patches or tapes.
- Patients with severe psychiatric illness or cognitive impairment.
- Long-term or high-dose opioid users.
- Patients utilizing a Patient-Controlled Analgesia (PCA) pump.
- Individuals with severe hepatic insufficiency or active liver disease.
- Vulnerable populations, individuals with restricted legal capacity, or those who are unable or unwilling to undergo clinical evaluations.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Super Vi PBM Patch - Soothing
The Super Vi PBM Patch - Soothing will be applied to the participant immediately upon arrival in the post-anesthesia care unit (PACU) after surgery.
|
A photobiomodulation (PBM) patch designed for postoperative pain relief.
The patch will be applied immediately upon arrival in the post-anesthesia care unit (PACU) after urological surgery.
|
|
Experimental: Super Vi PBM Patch - Soothing EX
The Super Vi PBM Patch - Soothing EX will be applied to the participant immediately upon arrival in the post-anesthesia care unit (PACU) after surgery.
|
A photobiomodulation (PBM) patch designed for postoperative pain relief.
The patch will be applied immediately upon arrival in the post-anesthesia care unit (PACU) after urological surgery.
|
|
Placebo-Komparator: Placebo Patch
The Placebo Patch will be applied to the participant immediately upon arrival in the post-anesthesia care unit (PACU) after surgery.
|
An placebo patch visually identical to the study patches but without therapeutic photobiomodulation delivery.
The patch will be applied immediately upon arrival in the post-anesthesia care unit (PACU) after urological surgery.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Time-Weighted Mean Visual Analogue Scale (VAS) Pain Score at Rest
Zeitfenster: Baseline (preoperatively), and 1 hour ±30 minutes, 2±1 hours, 6±2 hours, 12±2 hours, and 24±2 hours postoperatively
|
The preoperative baseline VAS pain score at rest will be recorded before surgery.
Postoperative VAS pain scores at rest will be assessed at 1 hour ±30 minutes, 2±1 hours, 6±2 hours, 12±2 hours, and 24±2 hours after surgery.
The time-weighted mean VAS pain score at rest (Scale: 0-100 mm; higher scores indicate worse pain) during the first 24 hours postoperatively will be analyzed using a mixed model for repeated measures (MMRM).
Sensitivity analysis will be performed using the area under the curve from baseline to 120 hours (AUC₀-₁₂₀h) with an analysis of covariance (ANCOVA) model.
|
Baseline (preoperatively), and 1 hour ±30 minutes, 2±1 hours, 6±2 hours, 12±2 hours, and 24±2 hours postoperatively
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Total Postoperative Analgesic Consumption
Zeitfenster: Up to 120 hours postoperatively
|
Comparison of the frequency and total dosage of analgesic use among the three groups within 120 hours postoperatively.
Analgesics include non-opioids (e.g., Acetaminophen, NSAIDs) and opioids (e.g., Morphine, Tramadol).
Opioid use will be converted to Morphine Milligram Equivalents (MME) for standardized comparison, in order to evaluate and verify the opioid-sparing effect of the study patch.
|
Up to 120 hours postoperatively
|
|
Proportion of Patients Achieving Patient Acceptable Symptom State (PASS)
Zeitfenster: 1 hour ±30 minutes, 2±1 hours, 6±2 hours, 12±2 hours, 24±2 hours, 48±2 hours, 72±2 hours, 96±2 hours, and 120±2 hours postoperatively
|
Proportion of participants in each group achieving Patient Acceptable Symptom State (PASS), defined as a Visual Analogue Scale (VAS) pain score of ≤33 mm (scale: 0-100 mm; higher scores indicate worse pain) at 1 hour ±30 minutes, 2±1 hours, 6±2 hours, 12±2 hours, 24±2 hours, 48±2 hours, 72±2 hours, 96±2 hours, and 120±2 hours postoperatively, used to assess patient satisfaction with pain control.
|
1 hour ±30 minutes, 2±1 hours, 6±2 hours, 12±2 hours, 24±2 hours, 48±2 hours, 72±2 hours, 96±2 hours, and 120±2 hours postoperatively
|
|
Clinical Recovery Progress
Zeitfenster: From end of surgery to hospital discharge, assessed up to 5 days postoperatively
|
Time to first ambulation out of bed and length of postoperative hospital stay will be recorded and compared among the three groups, to evaluate whether patch treatment accelerates the clinical recovery process.
|
From end of surgery to hospital discharge, assessed up to 5 days postoperatively
|
|
Quality of Life Improvement
Zeitfenster: Baseline (preoperative) to 120 hours postoperatively
|
Change in quality of life from preoperative baseline to 120 hours postoperatively, assessed using the Traditional Chinese version of the EQ-5D-5L questionnaire (EuroQol 5-Dimension 5-Level).
Higher index scores indicate better health-related quality of life.
The EQ Visual Analogue Scale (EQ-VAS) will be reported as a supplementary measure, with higher scores indicating better self-rated health.
|
Baseline (preoperative) to 120 hours postoperatively
|
|
Safety Assessment
Zeitfenster: Up to 120 hours postoperatively
|
Detailed recording of all adverse events occurring during the study period, including patch-site skin reactions (e.g., erythema, itching, rash) and analgesic-related side effects (e.g., nausea, vomiting, dizziness).
|
Up to 120 hours postoperatively
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 202603101DINA、202603107DINA
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .